Etanercept

Summary

Etanercept is a biologic disease-modifying antirheumatic drug (bDMARD) consisting of two extracellular domains of the human p75 TNF receptor fused to the Fc portion of human IgG1. It is approved for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It reduces inflammation and joint destruction by sequestering soluble TNF.

Mechanism of Action

Etanercept is a soluble decoy receptor that binds and neutralizes tumor necrosis factor-alpha (TNF-α) and TNF-β (lymphotoxin-alpha), preventing their interaction with cell-surface TNF receptors and thereby inhibiting downstream pro-inflammatory signaling.

Routes of Administration

Goals & Uses

• Management of psoriatic arthritisInflammatory/AutoimmuneHigh
• Treatment of plaque psoriasisDermatologyHigh
• Treatment of juvenile idiopathic arthritis (JIA)Pediatric RheumatologyHigh
• Treatment of ankylosing spondylitisInflammatory/AutoimmuneHigh
• Prevention of radiographic joint damageInflammatory/AutoimmuneHigh
• Reduction of signs and symptoms of rheumatoid arthritisInflammatory/AutoimmuneHigh

Contraindications

• Active serious infections (including sepsis)Infectious DiseaseHigh
• Moderate-to-severe heart failure (NYHA class III/IV)CardiovascularHigh
• Systemic lupus erythematosusAutoimmuneModerate
• Active tuberculosisInfectiousHigh
• Active hepatitis B infectionInfectious DiseaseHigh
• Hypersensitivity to etanercept or excipientsAllergyHigh

Adverse Effects

• Injection site reactionsLocalCommon
• Serious infections (bacterial, opportunistic, fungal)Infectious DiseaseUncommon
• Malignancy (lymphoma, solid tumors)OncologyRare
• Demyelinating disordersNeurologicalRare
• Tuberculosis reactivationInfectious DiseaseUncommon
• Upper respiratory tract infectionsInfectious DiseaseCommon

Drug Interactions

• AnakinraHigh
• Live vaccinesHigh
• CyclophosphamideModerate
• SulfasalazineModerate
• AbataceptHigh
• MethotrexateLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Patients with latent tuberculosis (untreated)Infectious DiseaseAbsolute
• Immunocompromised patientsImmunologicRelative
• Elderly (≥65 years)GeriatricRelative
• BreastfeedingReproductiveRelative
• Pediatric patients <2 yearsAgeAbsolute

Regulatory Status

• European UnionApprovedApproved: Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Axial spondyloarthritis (including ankylosing spondylitis), Plaque psoriasis (adults and children ≥6 years)Approved by EMA; biosimilars include Benepali, Erelzi, Nepexto, and others. Subject to additional monitoring in some biosimilar approvals.
• United StatesApprovedApproved: Rheumatoid arthritis (moderate-to-severe), Polyarticular juvenile idiopathic arthritis (≥2 years), Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis (moderate-to-severe, adults and pediatric ≥4 years)First approved by FDA in November 1998. Multiple biosimilars (Erelzi, Eticovo) approved. Black box warnings for serious infections and malignancies.
• United KingdomApprovedApproved: Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, Plaque psoriasisApproved via MHRA post-Brexit. Biosimilars available on NHS. NICE guidelines restrict use based on disease activity scores and prior therapy failure.

FDA-approved since 1998. Multiple biosimilars approved in the US and EU. Not recommended in active serious infections, active tuberculosis, or active hepatitis B. REMS not required but risk communication mandated regarding infections and malignancy.

Evidence & Sources

No sources recorded yet.